10-Q: Accuray Reports Q3 2025 Results: Revenue Up, Navigating Economic Headwinds

Accuray's Q3 2025 shows revenue growth amid ongoing challenges from supply chain issues, inflation, and macroeconomic uncertainties.

Summary

• Accuray Incorporated reported its financial results for the third quarter of fiscal year 2025, ended March 31, 2025.
• Net revenue increased by 12% to $113.2 million compared to $101.1 million in the same quarter of the previous year.
• Product revenue increased 16% to $57.3 million, while service revenue increased 9% to $55.9 million.
• The company reported a net loss of $1.3 million, or $0.01 per share, compared to a net loss of $6.3 million, or $0.06 per share, in the prior year's quarter.
• Gross orders decreased to $71.2 million from $89.1 million in the same period last year.
• The order backlog at the end of the period was $452.4 million.
• Accuray is navigating challenges related to inflation, supply chain disruptions, and geopolitical tensions, which are expected to continue impacting gross margins and cash flow through calendar year 2025.
• The company believes it has sufficient cash resources to fund operations for at least the next 12 months.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue and some financial metrics show improvement, the company faces ongoing economic and operational challenges. The outlook includes both positive growth and potential risks.

Positives

• Net revenue increased by 12% year-over-year.
• Product and service revenues both showed growth.
• Net loss improved compared to the same quarter last year.
• The company believes it has sufficient cash resources to fund operations for at least the next 12 months.
• The company has remediated previously disclosed material weaknesses in its system of internal controls as of March 31, 2025.

Negatives

• Gross orders decreased compared to the same period last year.
• The company is experiencing ongoing challenges related to inflation and supply chain disruptions.
• Reduced budgets and longer customer installation timelines in the United States are negatively impacting net revenue.
• The company has a significant accumulated deficit of $520.4 million.

Risks

• The company faces risks related to the current global economic environment, including inflation, high interest rates, and geopolitical concerns.
• The company's ability to achieve profitability depends on maintaining or increasing gross margins, which may be difficult.
• The company has outstanding indebtedness and may need to refinance its debt.
• The company is subject to risks arising from its international operations, including currency fluctuations and trade barriers.
• The company relies on single-source suppliers for critical components of its products.
• The company could become subject to product liability claims or product recalls.
• The company's industry is subject to intense competition and rapid technological change.
• The company's operating results may fluctuate from quarter to quarter and may be unpredictable.

Future Outlook

Accuray expects to navigate ongoing supply chain and inflation challenges, which are expected to continue impacting gross margins and cash flow through calendar year 2025. The company also anticipates that reduced budgets and longer customer installation timelines in the United States will continue to impact net revenue through fiscal year 2026.

Industry Context

The medical device industry, particularly in the radiation therapy sector, is highly competitive and subject to rapid technological advancements. Accuray faces competition from established players like Varian and Elekta, as well as emerging companies. The company's performance is influenced by factors such as healthcare reform, reimbursement policies, and the adoption of new technologies.

Comparison to Industry Standards

• Accuray competes with major players like Varian Medical Systems (a Siemens Healthineers company) and Elekta AB, both of which have greater market share and resources.
• Varian and Elekta offer conventional linac-based radiation therapy systems, which are a primary competitive alternative to Accuray's CyberKnife and TomoTherapy platforms.
• The report mentions that China represents a significantly underserved market for linacs, suggesting that Accuray's joint venture is strategically positioned to capitalize on this growth opportunity.
• The company's book-to-bill ratio of 1.2 indicates strong demand for its products, which is a positive sign compared to industry averages.

Management Changes

Stakeholder Impact

• Shareholders: The company's performance and future outlook will impact shareholder value.
• Customers: Ongoing supply chain challenges and longer installation timelines may affect customers.
• Employees: The company's cost-saving initiatives and potential restructuring may impact employees.
• Creditors: The company's ability to refinance its debt is crucial for its financial stability.

Next Steps

• The company will continue to critically review its liquidity and anticipated capital requirements.
• The company will continue to evaluate the impact of the tax law change in future periods.
• The company plans to adopt ASU 2023-09 on July 1, 2025.
• The company plans to adopt ASU 2024-03 on July 1, 2027.

Key Dates

Keywords

Accuray, revenue, financial results, radiation therapy, CyberKnife, TomoTherapy, net loss, gross orders, backlog, inflation, supply chain, economic conditions, joint venture, China